Heterogeneous treatment effects of sodium‐glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population‐based cohort study

Abstract INTRODUCTION Sodium-glucose cotransporter 2 (SGLT2) inhibitors exhibit potential benefits in reducing dementia risk, yet the optimal beneficiary subgroups remain uncertain. METHODS Individuals with type 2 diabetes (T2D) initiating either SGLT2 inhibitor or...